LGD-Xtreme — Class II drug recall D-0910-2016
Ongoing recall by Invisiblu International LLC, reported 2016-06-08, distributed nationwide. Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033
| Recall number | D-0910-2016 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Invisiblu International LLC, Fort Lauderdale, FL, United States |
| Recall initiated | 2016-03-31 |
| Classified | 2016-05-27 |
| Reported by FDA | 2016-06-08 |
| Distributed | Nationwide (US) |
| Countries outside the US | BR |
| Quantity | 3,319 bottles |
| Reason classes | unapproved product |
| Lot numbers | 11/18, 21511166 |
Product
LGD-Xtreme (ligandrol LGD-4033),capsules, 3 mg, 90-count bottle, Manufactured for Continuum Labs, Fort Lauderdale, FL
Reason for recall
Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0910-2016. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.